DelveInsight’s, “ROS1 Protein Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in ROS1 Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
ROS1 Protein Inhibitors: Overview
ROS1 is a pivotal transmembrane receptor protein tyrosine kinase which regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. There is increasing evidence supporting that ROS1 plays an important role in different malignancies including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and non small cell lung cancer; thus, ROS1 has become a potential drug discovery target. ROS1 shares about 49% sequence homology with ALK primary structure; therefore, wide range of ALK kinase inhibitors have shown in vitro inhibitory activity against ROS1 kinase.
The companies and academics are working to assess challenges and seek opportunities that could influence ROS1 Protein Inhibitors R&D. The therapies under development are focused on novel approaches for ROS1 Protein Inhibitors.
This segment of the ROS1 Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ROS1 Protein Inhibitors Emerging Drugs
Alkotinib: Suzhou Zelgen Biopharmaceuticals
Alkotinib Capsules are being tested in two Phase II clinical trials for the efficacy and safety of ALK-positive patients with advanced NSCLC for whom the Crizotinib therapy fails and for ALK-positive, non-small cell lung cancer patients with brain metastases.
APG-2449: Ascentage Pharma
APG-2449 is a potent, orally bioavailable inhibitor of the focal adhesion kinase, or FAK, ROS1 and anaplastic lymphoma kinase, or ALK, kinases, which we are developing for the treatment of cancer. APG-2449 has demonstrated antitumor activity in multiple xenograft tumor models. Studies in preclinical tumor models have shown that APG-2449 overcomes the drug resistance to the first generation ALK inhibitors, and exhibits synergistic effects with EGFR inhibitors (especially the newly approved third generation AZD9291/osimertinib) in an EGFRT790M mutant NSCLC xenograft tumor model.
Further product details are provided in the report……..
This segment of the report provides insights about the different ROS1 Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the ROS1 Protein Inhibitors. The companies which have their ROS1 Protein Inhibitors drug candidates in the most advanced stage, i.e. Phase II include Suzhou Zelgen Biopharmaceuticals.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
ROS1 Protein Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses ROS1 Protein Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ROS1 Protein Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
ROS1 Protein Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
ROS1 Protein Inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Ensartinib: Xcovery
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Alkotinib: Suzhou Zelgen Biopharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
APG-2449: Ascentage Pharma
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
ROS1 Protein Inhibitors Key Companies
ROS1 Protein Inhibitors Key Products
ROS1 Protein Inhibitors- Unmet Needs
ROS1 Protein Inhibitors- Market Drivers and Barriers
ROS1 Protein Inhibitors- Future Perspectives and Conclusion
ROS1 Protein Inhibitors Analyst Views
ROS1 Protein Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for ROS1 Protein Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for ROS1 Protein Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Suzhou Zelgen Biopharmaceuticals
• Ascentage Pharma
• Xuanzhu Biopharmaceutical
• Pfizer
• Turning Point Therapeutics
• Roche
• Fochon Pharma
• Eli Lilly and Company
• Daiichi Sankyo Inc
• Chia Tai Tianqing Pharmaceutical Group
• Xcovery
